119 related articles for article (PubMed ID: 33583762)
21. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
22. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
23. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
[TBL] [Abstract][Full Text] [Related]
24. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
25. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
26. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Rathkopf DE; Morris MJ; Fox JJ; Danila DC; Slovin SF; Hager JH; Rix PJ; Chow Maneval E; Chen I; Gönen M; Fleisher M; Larson SM; Sawyers CL; Scher HI
J Clin Oncol; 2013 Oct; 31(28):3525-30. PubMed ID: 24002508
[TBL] [Abstract][Full Text] [Related]
28. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
29. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
[TBL] [Abstract][Full Text] [Related]
30. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
Chesnut GT; Vertosick EA; Benfante N; Sjoberg DD; Fainberg J; Lee T; Eastham J; Laudone V; Scardino P; Touijer K; Vickers A; Ehdaie B
Eur Urol; 2020 Apr; 77(4):501-507. PubMed ID: 31874726
[TBL] [Abstract][Full Text] [Related]
31. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
33. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
34. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Qin X; Ji D; Gu W; Han W; Luo H; Du C; Zou Q; Sun Z; He C; Zhu S; Chong T; Yao X; Wan B; Yang X; Bai A; Jin C; Zou J; Ye D
BMC Med; 2022 Mar; 20(1):84. PubMed ID: 35241087
[TBL] [Abstract][Full Text] [Related]
35. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
[TBL] [Abstract][Full Text] [Related]
36. Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Baron B; Hirmand M; Smith MR
Eur Urol; 2015 Nov; 68(5):787-94. PubMed ID: 25687533
[TBL] [Abstract][Full Text] [Related]
37. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
38. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
39. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
40. Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
Schweizer MT; True L; Gulati R; Zhao Y; Ellis W; Schade G; Montgomery B; Goyal S; Nega K; Hakansson AK; Liu Y; Davicioni E; Pienta K; Nelson PS; Lin D; Wright J
J Urol; 2023 Feb; 209(2):354-363. PubMed ID: 36621991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]